How to buy Curis stock (CRIS)

Curis is a biotechnology business based in the US. Curis shares (CRIS) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.08 – a decrease of 13.73% over the previous week. Curis employs 49 staff and has a trailing 12-month revenue of around $10.2 million.

Our top picks for where to buy Curis stock

Buy Curis stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Curis stock price (NASDAQ: CRIS)

Use our graph to track the performance of CRIS stocks over time.

Curis shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$3.08
52-week range	$3.22 - $17.49
50-day moving average more info button	$4.41
200-day moving average more info button	$7.88
Wall St. target price	$21.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-7.77

Is it a good time to buy Curis stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Curis price performance over time

Historical closes compared with the close of $3.07 from 2024-12-19

1 week (2024-12-13)	-14.01%
1 month (2024-11-21)	-25.12%
3 months (2024-09-20)	-48.05%
6 months (2024-06-21)	-61.43%

1 year (2023-12-21)	-75.81%
2 years (2022-12-21)	-69.31%
3 years (2021-12-21)	97.6
5 years (2019-12-20)	30.8

Curis financials

Revenue TTM	$10.2 million
Gross profit TTM	$-33,372,000
Return on assets TTM	-45.97%
Return on equity TTM	-372.68%
Profit margin	0%
Book value	$3.34
Market Capitalization more info button	$27.3 million

TTM: trailing 12 months

Curis share dividends

We're not expecting Curis to pay a dividend over the next 12 months.

Have Curis's shares ever split?

Curis's shares were split on a 1:5 basis on 29 May 2018 . So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Curis shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Curis shares which in turn could have impacted Curis's share price.

Curis share price volatility

Over the last 12 months, Curis's shares have ranged in value from as little as $3.22 up to $17.49. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Curis's is 3.349. This would suggest that Curis's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Curis overview

Curis, Inc. , a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc. , or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib.

Frequently asked questions

null
What percentage of Curis is owned by insiders or institutions?
Currently 6.776% of Curis shares are held by insiders and 24.366% by institutions. How many people work for Curis?
Latest data suggests 49 work at Curis. When does the fiscal year end for Curis?
Curis's fiscal year ends in December. Where is Curis based?
Curis's address is: Building C, Lexington, MA, United States, 02421 What is Curis's ISIN number?
Curis's international securities identification number is: US2312692005 What is Curis's CUSIP number?
Curis's Committee on Uniform Securities Identification Procedures number is: 231269200